Breaking News Instant updates and real-time market news.

DO

Diamond Offshore

, SOHU

Sohu.com

$50.85

1.87 (3.82%)

09:18
07/31/17
07/31
09:18
07/31/17
09:18

On The Fly: Pre-market Movers

UP AFTER EARNINGS: Diamond Offshore (DO), up 2.9%... Sohu.com (SOHU), up 8.6%... Sanofi (SNY), up 1.1%... Alliance Resource Partners (ARLP), up 2.2%... New Residential Investment (NRZ), up 5.4%... HSBC (HSBC), up 1.9%. ALSO HIGHER: Altaba (AABA), up 1.4% after announcing a $5B share repurchase program... GoPro (GPRO), up 2.5% after being upgraded to Equal Weight from Underweight at Morgan Stanley. NOTABLE MOVERS: Scripps Networks (SNI) is up 1.2% following the announcement that Discovery (DISCA) will acquire the company for $90 per share in a cash and stock transaction valued at $14.6B. Discovery is down just under 1%. LOWER: Facebook (FB), down marginally after being downgraded to Sell from Hold at Pivotal Research... Changyou.com (CYOU), down 2.3% after reporting quarterly results... Clovis (CLVS), down 7.4% after entering into a clinical collaboration agreement to evaluate the combination of Bristol-Myers (BMY) immunotherapy Opdivo and Clovis Oncology's poly, or ADP-ribose, polymerase, or PARP, inhibitor Rubraca in pivotal phase 3 clinical trials.

DO

Diamond Offshore

SOHU

Sohu.com

$50.85

1.87 (3.82%)

SNY

Sanofi

ARLP

Alliance Resource Partners

$20.05

0.15 (0.75%)

NRZ

New Residential

HSBC

HSBC

AABA

Altaba

$59.20

0.77 (1.32%)

GPRO

GoPro

$8.10

0.04 (0.50%)

SNI

Scripps Networks

$86.91

0.5 (0.58%)

DISCA

Discovery

$26.80

0.41 (1.55%)

FB

Facebook

$172.45

2.01 (1.18%)

CYOU

Changyou.com

$42.98

0.19 (0.44%)

CLVS

Clovis

$98.02

5.77 (6.25%)

  • 31

    Jul

  • 31

    Jul

  • 31

    Jul

  • 31

    Jul

  • 31

    Jul

  • 31

    Jul

  • 31

    Jul

  • 31

    Jul

  • 02

    Aug

  • 03

    Aug

  • 09

    Aug

  • 16

    Aug

  • 18

    Aug

  • 29

    Aug

  • 08

    Sep

  • 13

    Sep

  • 14

    Nov

DO Diamond Offshore

06/21/17
GHSC
06/21/17
DOWNGRADE
GHSC
Sell
Diamond Offshore downgraded to Sell from Neutral at Seaport Global
03/16/17
RAJA
03/16/17
NO CHANGE
RAJA
Market Perform
Raymond James raises Diamond Offshore EBITDA estimates on Ocean Valor ruling
Raymond James analyst Praveen Narra called a Brazilian court ruling on the side of Diamond Offshore (DO) in the case of the Ocean Valor termination with Petrobras (PBR) a "surprise" and upped his EBITDA estimates for FY17 and FY18 based on the decision. He expects the stock to react positively to the news, but maintains a Market Perform rating on Diamond citing the current point in the offshore cycle. Diamond Offshore shares are up 1.7% to $15.64 in early trading.
02/07/17
PART
02/07/17
UPGRADE
PART
Hold
Diamond Offshore upgraded to Hold from Sell at Pareto
reaPareto analyst Bard Rosef upgraded Diamond Offshore to Hold.
06/30/17
BOFA
06/30/17
DOWNGRADE
BOFA
Neutral
Diamond Offshore downgraded to Neutral from Buy at BofA/Merrill
SOHU Sohu.com
$50.85

1.87 (3.82%)

04/18/17
BNCH
04/18/17
INITIATION
BNCH
Hold
Sohu.com initiated with a Hold at Benchmark
Benchmark analyst Fawne Jiang initiated Sohu.com with a Hold rating.
05/23/17
HSBC
05/23/17
DOWNGRADE
HSBC
Hold
Sohu.com downgraded to Hold from Buy at HSBC
08/31/16
08/31/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BTIG initiated coverage of Juno Therapeutics (JUNO) with a Sell rating, saying the firm is "generally skeptical of current investor expectations for the CD19 CAR T market." The firm has a fair value estimate on Juno of $23 per share. 2. JPMorgan analyst Alex Yao assumed coverage of Sohu.com (SOHU) with an Underweight rating and $40 price target. The rating is unchanged and the price target is lowered from $47. The company will find it difficult to come up with new initiatives to address the continued decline in games revenue, Yao tells investors in a research note. 3. JPMorgan's Yao assumed coverage of SINA (SINA) with an unchanged Overweight rating and $123 price target. 4. Jefferies analyst Jason Kupferberg started First Data (FDC) with a Buy rating and $16.50 price target. Growth in the company's domestic merchant processing segment is set to inflect, the analyst tells investors in a research note. 5. Baird analyst William Power initiated j2 Global (JCOM) with an Outperform rating and $83 price target, citing its attractive valuation, strong free cash flow, consistent margin expansion, the growth in digital media, and its disciplined acquisition strategy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/09/16
DBAB
09/09/16
INITIATION
Target $53.3
DBAB
Buy
Sohu.com reinstated with a Buy at Deutsche Bank
Deutsche Bank analyst Michael Tong reinstated Sohu.com with a Buy rating and $53.30 price target.
SNY Sanofi

06/27/17
FBCO
06/27/17
NO CHANGE
FBCO
Outperform
Alnylam price target raised to $96 from $90 at Credit Suisse
Credit Suisse analyst Alethia Young increased her probability of success for Alnylam's (ALNY) givosian in porphyria to 60% from 40% and keeps an estimate of unadjusted peak sales of $475M, while also noting that the fact that Sanofi (SNY) did not opt into the porphyria program, meaning Alnylam receives full economics. Given the higher chances ascribed to success, Young raised her price target on Alnylam to $96 from $90 and keeps an Outperform rating on the stock.
07/14/17
WELS
07/14/17
NO CHANGE
Target $41
WELS
Outperform
Wells says smallpox vaccine deal an 'excellent fit' for Emergent BioSolutions
Wells Fargo analyst David Maris said Emergent BioSolutions' (EBS) deal to acquire the ACAM2000 smallpox vaccine business of Sanofi (SNY) is "an excellent fit" and he is "encouraged" by its ability to identify and make a deal for such a "solid target." Maris keeps an Outperform rating and $41 price target on Emergent BioSolutions.
07/31/17
PIPR
07/31/17
NO CHANGE
Target $557
PIPR
Overweight
Regeneron indicated lower after Sanofi earnings report, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says shares of Regeneron (REGN) are indicated lower after partner Sanofi (SNY) reported Q2 U.S. Dupixent sales of $30M in adults with atopic dermatitis. This was essentially in line with the consensus estimate of $33M, Tenthoff tells investors in a research note. He adds that over 5,100 physicians have prescribed and over 13,000 atopic dermatitis patients have been prescribed Dupixent as of July 26. The analyst views the launch stats as impressive and reiterates an Overweight rating on Regeneron with a $557 price target.
07/10/17
PIPR
07/10/17
NO CHANGE
Target $126
PIPR
Overweight
Alnylam shares overreacting to ALT elevations in OLE data, says Piper Jaffray
Alnylam (ALNY) and partner Sanofi (SNY) presented new Phase II open-label extension study data on 33 hemophilia patients being treated with fitusiran and reported that eleven patients reported asymptomatic ALT increases, up from three observed in its ASH meeting update, noted Piper Jaffray analyst Edward Tenthoff. However, he thinks the stock is overreacting, as the liver enzyme elevations were asymptomatic and largely reversed within one month, he tells investors. Tenthoff, who also sees the efficacy data as encouraging, reiterates his Overweight rating and $126 price target on Alnylam shares.
ARLP Alliance Resource Partners
$20.05

0.15 (0.75%)

02/01/17
HDLY
02/01/17
UPGRADE
HDLY
Long-Term Buy
Alliance Resource upgraded to Long-Term Buy from Neutral at Hilliard Lyons
12/20/16
MKMP
12/20/16
INITIATION
MKMP
Neutral
Alliance Resource Partners initiated with a Neutral at MKM Partners
MKM Partners analyst Daniel Scott initiated Alliance Resource Partners with a Neutral and a $25 price target saying he expects headwinds to continue for several quarters and is looking for real signs of a pricing recovery.
10/31/16
GHSC
10/31/16
INITIATION
Target $29
GHSC
Buy
Alliance Resource Partners initiated with a Buy at Seaport Global
Seaport Global initiated Alliance Resource Partners with a Buy and a $29 price target citing its top notch management, pristine balance sheet, and attractive valuation.
NRZ New Residential

05/02/17
COMP
05/02/17
DOWNGRADE
Target $3.5
COMP
Neutral
Ocwen downgraded to Neutral on valuation at Compass Point
Compass Point analyst Fred Small downgraded Ocwen to Neutral from Buy after the over 40% jump in shares following the announcement of a strategic deal with New Residential (NRZ) yesterday. The analyst maintained a $3.50 price target on Ocwen shares and recommends moving to the sidelines until viability into long-term earnings power emerges.
05/16/17
PIPR
05/16/17
NO CHANGE
Target $18
PIPR
Overweight
New Residential target raised to $18 after CEO meeting at Piper Jaffray
Piper Jaffray analyst Kevin Barker raised his price target for New Residential Investment (NRZ) after hosting meetings with the company's CEO Michael Nierenberg. The analyst has increased confidence that the Ocwen (OCN) mortgage servicing rights deal will be "meaningfully accretive" to New Residential and provide support for a higher dividend in the future. Barker reiterates an Overweight rating on the shares.
06/20/17
WEDB
06/20/17
DOWNGRADE
WEDB
Neutral
New Residential downgraded to Neutral from Outperform at Wedbush
06/20/17
WEDB
06/20/17
DOWNGRADE
WEDB
Neutral
New Residential downgraded on downward rates, regulatory worries at Wedbush
As noted earlier, before the market opened, Wedbush downgraded New Residential (NRZ) to Neutral from Outperform Analyst Jason Weaver downgraded the stock based on falling interest rates and his belief that the CFPB and Florida's attorney general could seek to sue New Residential as part of their lawsuit against Ocwen (OCN). The analyst does not expect New Residential to be hurt by any such lawsuits, but he says that they would create headline risk for the company and could delay the closing of its deal with Ocwen. Target to $16.50 from $17.
HSBC HSBC

07/24/17
LYON
07/24/17
UPGRADE
LYON
Outperform
HSBC upgraded to Outperform from Sell at CLSA (pre-open)
CLSA analyst Asheefa Sarangi upgraded HSBC two notches to Outperform given stronger-than-expected asset quality, resulting in an upward revision to 2017 estimates. Looking to 2018-19, Asheefa believes new management will focus on balance sheet growth with a greater willingness to move up the risk curve.
07/04/17
BREN
07/04/17
DOWNGRADE
BREN
Hold
HSBC downgraded to Hold from Buy at Berenberg
Berenberg analyst James Chappell downgraded saying he views the shares as fully valued at current levels. The analyst has a 600p price target for the stock.
06/28/17
MSCO
06/28/17
UPGRADE
MSCO
Overweight
HSBC upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Chris Manners upgraded HSBC to Overweight saying he expects deployment of excess capital to become a focus of investors and said actions to control RWAs is underappreciated.
01/19/17
EXAN
01/19/17
UPGRADE
EXAN
Outperform
HSBC upgraded to Outperform from Neutral at Exane BNP Paribas (yesterday)
AABA Altaba
$59.20

0.77 (1.32%)

07/17/17
UBSW
07/17/17
NO CHANGE
Target $69
UBSW
Buy
Altaba price target raised to $69 from $58 at UBS
UBS analyst Eric Sheridan raised his price target on Altaba (AABA) to $69 from $58 following its transformation from Yahoo. The analyst said tax efficient structures could allow the company to monetize its Alibaba (BABA) and Yahoo Japan stakes and the possibility of a federal tax cut provides additional optionality for tax efficiency. Sheridan reiterated his Buy rating on Altaba shares.
06/28/17
JPMS
06/28/17
INITIATION
Target $65
JPMS
Overweight
Altaba initiated with an Overweight at JPMorgan
JPMorgan analyst Doug Anmuth started Altaba (AABA) with an Overweight rating and $65 price target. The analyst cites expected upside in Alibaba (BABA), the ability for Altaba to close its 31% valuation discount over time, and expected Yahoo Japan (YAHOY) upside for his bullish thesis.
06/28/17
06/28/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Altaba (AABA) initiated with an Overweight at JPMorgan. 2. Aetna (AET) and Humana (HUM) were initiated with a Buy at Citi. The firm also added Aetna to its Focus List. 3. CVS Health (CVS) and Walgreens Boots Alliance (WBA) were initiated with a Hold at Needham. 4. Oaktree Capital (OAK) initiated with a Hold at Jefferies. 5. General Motors (GM) resumed with an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
GPRO GoPro
$8.10

0.04 (0.50%)

07/31/17
07/31/17
UPGRADE
Target $7.5

Equal Weight
GoPro upgraded to Equal Weight on valuation at Morgan Stanley
As previously reported, Morgan Stanley upgraded GoPro to Equal Weight from Underweight with a $7.50 price target. Analyst Yuuji Anderson said valuation better reflects efforts to driver better product cycles through software improvements.
07/31/17
MSCO
07/31/17
UPGRADE
MSCO
Equal Weight
GoPro upgraded to Equal Weight from Underweight at Morgan Stanley
04/27/17
ADAM
04/27/17
NO CHANGE
Target $72
ADAM
Buy
Ambarella has compelling potential opportunity with Amazon, says Canaccord
Canaccord analyst Matthew Ramsay believes the future of Ambarella (AMBA) will be driven by a combination of image capture and computer vision artificial intelligence processing in several end markets, including security, drone, and automotive cameras. Ramsay believes its first computer vision application will come in Amazon's (AMZN) new Echo Look camera. He believes despite the decline of GoPro (GPRO) business, investors are beginning to understand Ambarella's complex sensor fusion logic algorithm and computer vision hardware roadmaps. Ramsay reiterated his Buy rating and $72 price target on Ambarella shares.
06/07/17
ADAM
06/07/17
NO CHANGE
Target $72
ADAM
Buy
Ambarella transition to continue for several quarters, says Canaccord
Canaccord analyst Matthew Ramsay noted Ambarella reported better than expected Q1 results reflecting strength in several end markets, including professional and home security, automotive, wearable cameras, offset by a decline in drone sales from Tier-2 customers. The company maintained flat guidance while the analyst believes the company will remain in transition until the computer vision family of products is detailed further to investors. Ramsay maintained his Buy rating and $72 price target on Ambarella shares.
SNI Scripps Networks
$86.91

0.5 (0.58%)

07/25/17
NEED
07/25/17
NO CHANGE
NEED
Hold
Needham likes Scripps Networks best as Discovery merger partner
Needham analyst Laura Martin believes Discovery (DISCA) will decide to protect its U.S. asset value rather than exit, and likes Scripps Networks (SNI) best as a merger partner for the company. The analyst reiterates a Hold rating on Discovery's shares.
07/20/17
07/20/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with a Neutral at Citi. 2. Johnson & Johnson (JNJ) reinstated with an Outperform at Credit Suisse. 3. Tile Shop (TTS) initiated with a Hold at Loop Capital. 4. Spring Bank Pharmaceuticals (SBPH) initiated with an Overweight at Cantor. 5. Discovery (DISCA) and Scripps Networks (SNI) were initiated with a Market Perform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/26/17
WELS
07/26/17
NO CHANGE
WELS
Scripps Networks could be acquired for $91-$95 per share, says Wells Fargo
After the Wall Street Journal reported that Discovery (DISCA) and Viacom (VIAB) are interested in buying Scripps' (SNI) assets, Wells Fargo estimates that Scripps could be acquired for $91-$95 per share. The firm believes that the acquirer or acquirers could realize a total of about $175M of non-programming expense synergies. It keeps a Market Perform rating on Scripps.
07/20/17
WELS
07/20/17
INITIATION
WELS
Market Perform
Scripps Networks initiated with a Market Perform at Wells Fargo
Wells Fargo started coverage of Scripps with an $82 price target and a Market Perform rating. The firm says the company has a number of strengths, including "very low affiliate fees, extremely high engagement, an educated female audience," better ratings than peers and continued ad revenue growth of around 5%. However, the firm says it doesn't necessarily believe that Discovery (DISCA) is "the right partner" for Scripps, and "it's tough to get overly excited" about Scripps at the current stock price.
DISCA Discovery
$26.80

0.41 (1.55%)

FB Facebook
$172.45

2.01 (1.18%)

07/27/17
NEED
07/27/17
NO CHANGE
Target $185
NEED
Buy
Facebook 'strong over-delivery' a negative for Snap, says Needham
Needham analyst Laura Martin believes Facebook's (FB) "strong over-delivery" of Q2 earnings is negative for Snap (SNAP) because Instagram Stories hit 250M DAU's in Q2, well above Snap's 166M DAU's in Q1. The analyst reiterates a Buy rating and $185 price target on Facebook's shares.
07/27/17
UBSW
07/27/17
NO CHANGE
Target $190
UBSW
Buy
Facebook price target raised to $190 from $168 at UBS
UBS analyst Eric Sheridan raised his price target on Facebook to $190 from $168 following Q2 results. The analyst said its across the board strength should sustain the stock's price momentum. Sheridan reiterated his Buy rating on Facebook shares.
07/27/17
JMPS
07/27/17
NO CHANGE
JMPS
Facebook price target raised to $195 from $170 at JMP Securities
JMP Securities analyst Ronald Josey believes that Facebook's Q2 results shows that higher ad prices can offset declines in ad loads. The analyst says that the company's "core fundamentals" are strong, and he keeps an Outperform rating on the shares.
07/31/17
PIVT
07/31/17
DOWNGRADE
Target $140
PIVT
Sell
Facebook downgraded to Sell from Hold at Pivotal Research
Pivotal Research analyst Brian Wieser downgraded Facebook (FB) to Sell with an unchanged price target of $140. The social network closed Friday up $2.01 to $172.45. The shares are not factoring in risks to the company's growth following their "remarkable run" this year, Wieser tells investors in a research note. The recent European Commission ruling on Google (GOOG, GOOGL) Shopping and the agency's approach to dominant companies in general poses a greater risk as Facebook becomes larger, the analyst contends.
CYOU Changyou.com
$42.98

0.19 (0.44%)

04/18/17
BNCH
04/18/17
INITIATION
BNCH
Hold
Changyou.com initiated with a Hold at Benchmark
Benchmark analyst Fawne Jiang initiated Changyou.com with a Hold rating.
02/24/17
MSCO
02/24/17
UPGRADE
Target $27
MSCO
Equal Weight
Changyou.com upgraded to Equal Weight on moble game revenue at Morgan Stanley
As previously reported, Morgan Stanley upgraded Chanyou.com to Equal Weight from Underweight and raised its price target to $27 from $17. Analyst Grace Chen is incrementally more positive on mobile game revenue and believes cooperation with Tencent in the key game titles will help Chanyou in improving game distribution operating efficiency.
05/23/17
HSBC
05/23/17
DOWNGRADE
HSBC
Hold
Changyou.com downgraded to Hold from Buy at HSBC
06/05/17
SBSH
06/05/17
UPGRADE
SBSH
Neutral
Changyou.com upgraded to Neutral from Sell at Citi
CLVS Clovis
$98.02

5.77 (6.25%)

07/27/17
JANY
07/27/17
NO CHANGE
Target $107
JANY
Buy
PARP deals may make Clovis more attractive buyout candidate, says Janney
The partnerships announced today between AstraZeneca (AZN) and Merck (MRK) as well as Tesaro (TSRO) and Takeda highlight pharma's willingness to expand on PARP's, Janney analyst Debjit Chattopadhyay tells investors in a research note. Clovis' (CLVS) Rubraca is now the only unencumbered PARP and is "far cheaper" on a relative valuation basis than peer Tesaro, the analyst adds. He believes Clovis could now become a more compelling takeover candidate. Chattopadhyay has a Buy rating on the shares with a $107 price target. The stock in midday trading is up 7%, or $5.90, to $93.33.
07/27/17
FBCO
07/27/17
NO CHANGE
FBCO
Merck unlikely to buy PARP company after Astra deal, says Credit Suisse
Credit Suisse analyst Alethia Young believes Merck (MRK) is unlikely to acquire a PARP inhibitor company like Tesaro (TSRO) or Clovis (CLVS) after inking an immuno-oncology deal with AstraZeneca (AZN).
06/22/17
OPCO
06/22/17
INITIATION
OPCO
Perform
Clovis initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Clovis with a Perform rating.
06/22/17
RHCO
06/22/17
NO CHANGE
RHCO
Clovis price target raised to $105 from $85 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Clovis based on his belief that the company's PARP inhiobitor, Rubraca, showed "striking efficacy in all three cohorts" of a study. The analyst thinks that the drug will be approved in second phase and later ovarian cancer. He keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

KSU

Kansas City Southern

$105.80

-0.07 (-0.07%)

17:45
08/18/17
08/18
17:45
08/18/17
17:45
Hot Stocks
Kansas City Southern director Henry Maier buys 3,000 shares »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

RXII

RXi Pharmaceuticals

$0.58

-0.02 (-3.36%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Syndicate
Breaking Syndicate news story on RXi Pharmaceuticals »

RXi Pharmaceuticals files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

WIN

Windstream

$1.98

0.06 (3.13%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Hot Stocks
Windstream CEO acquires 25,381 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$2.44

-0.22 (-8.27%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Syndicate
Breaking Syndicate news story on CEL-SCI »

CEL-SCI files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRN

Trinity Industries

$28.20

-0.03 (-0.11%)

17:25
08/18/17
08/18
17:25
08/18/17
17:25
Hot Stocks
ValueAct raises stake inTrinity Industries to 11% from 9.8% »

As of this date, ValueAct…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPTN

Lpath

17:11
08/18/17
08/18
17:11
08/18/17
17:11
Hot Stocks
Breaking Hot Stocks news story on Lpath »

Stonepine Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGR

Progressive

$48.63

0.12 (0.25%)

17:08
08/18/17
08/18
17:08
08/18/17
17:08
Hot Stocks
Progressive CFO sells 50,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMO

Thermo Fisher

$172.57

-0.32 (-0.19%)

17:06
08/18/17
08/18
17:06
08/18/17
17:06
Hot Stocks
Thermo Fisher director sells 11,318 shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

SMBC

Southern Missouri Bancorp

$31.18

-0.05 (-0.16%)

17:06
08/18/17
08/18
17:06
08/18/17
17:06
Hot Stocks
Southern Missouri Bancorp and Southern Missouri Bancshares to merge »

Southern Missouri Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:58
08/18/17
08/18
16:58
08/18/17
16:58
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says ended advisory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:57
08/18/17
08/18
16:57
08/18/17
16:57
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says ending…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:57
08/18/17
08/18
16:57
08/18/17
16:57
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says never had…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:56
08/18/17
08/18
16:56
08/18/17
16:56
Hot Stocks
Icahn no longer special advisor to President Trump on regulatory reform issues »

Carl Icahn, founder of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVTA

Invitae

$9.60

0.05 (0.52%)

16:55
08/18/17
08/18
16:55
08/18/17
16:55
Syndicate
Breaking Syndicate news story on Invitae »

Invitae files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVTA

Invitae

$9.60

0.05 (0.52%)

16:49
08/18/17
08/18
16:49
08/18/17
16:49
Syndicate
Breaking Syndicate news story on Invitae »

Invitae files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$30.38

0.76 (2.57%)

16:48
08/18/17
08/18
16:48
08/18/17
16:48
Hot Stocks
Micron director sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 06

    Sep

INSY

Insys Therapeutics

$9.17

-0.11 (-1.19%)

16:42
08/18/17
08/18
16:42
08/18/17
16:42
Hot Stocks
Insys agrees to pay $4.45M to settle opioid marketing suit »

Illinois Attorney General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKTX

Akari Therapeutics

16:34
08/18/17
08/18
16:34
08/18/17
16:34
Syndicate
Breaking Syndicate news story on Akari Therapeutics »

Akari Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JMBA

Jamba

$9.11

-0.04 (-0.44%)

16:32
08/18/17
08/18
16:32
08/18/17
16:32
Hot Stocks
Jamba receives expected letter from Nasdaq »

Jamba, Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIL

Hill International

$4.50

0.2 (4.65%)

16:31
08/18/17
08/18
16:31
08/18/17
16:31
Hot Stocks
Hill International receives NYSE notice regarding late Form 10-Q filing »

Hill International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$55.65

-0.47 (-0.84%)

16:30
08/18/17
08/18
16:30
08/18/17
16:30
Periodicals
Target ends relationship with food startup Hampton Creek, Bloomberg says »

After an internal review,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
08/18/17
08/18
16:30
08/18/17
16:30
Options
Preliminary option volume of 23.2M today »

Preliminary option volume…

NBEV

New Age Beverages

$3.51

-0.49 (-12.25%)

16:29
08/18/17
08/18
16:29
08/18/17
16:29
Hot Stocks
New Age Beverages director sells nearly 42,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ATW

Atwood Oceanics

$6.26

0.22 (3.64%)

, ESV

Ensco

$4.28

0.12 (2.88%)

16:24
08/18/17
08/18
16:24
08/18/17
16:24
Hot Stocks
Atwood Oceanics, Ensco file proxy materials in connection with pending merger »

Ensco (ESV) and Atwood…

ATW

Atwood Oceanics

$6.26

0.22 (3.64%)

ESV

Ensco

$4.28

0.12 (2.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$83.76

-0.1 (-0.12%)

16:23
08/18/17
08/18
16:23
08/18/17
16:23
Periodicals
Nestle faces potential fraud suit over Poland Spring marketing, WSJ says »

Nestle is facing a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.